08:38 AM EDT, 03/14/2025 (MT Newswires) -- Korro Bio ( KRRO ) said Friday that the US Food and Drug Administration has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of alpha-1 antitrypsin deficiency, or AATD.

AATD is a genetic disorder that can cause pulmonary emphysema and/or hepatic cirrhosis, Korro Bio ( KRRO ) said.

Korro Bio ( KRRO ) chief medical officer Dr. Kemi Olugemo said that KRRO-110 "has the potential to treat both liver and lung manifestations" of the disease.